Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
As the world’s largest dedicated animal-health company, Zoetis divides its revenue between companion-animal vaccines and production-livestock therapeutics. That split makes every Zoetis 10-K a deep dive into pet-care demand, feedlot economics, and veterinary R&D pipelines—details investors can’t afford to miss.
Stock Titan gathers every Zoetis SEC filing in one place and layers in AI-powered summaries that turn dense disclosures into plain-English insights. Whether you need the Zoetis quarterly earnings report 10-Q filing to track segment margins, crave Zoetis Form 4 insider transactions real-time, or want the Zoetis proxy statement executive compensation broken down, our platform delivers. We link each form to the question it answers: 8-K material events explained when supply constraints hit, the Zoetis annual report 10-K simplified for vaccine pipeline updates, and Zoetis insider trading Form 4 transactions pushed to you immediately.
Here’s how professionals use the page:
- Track Zoetis executive stock transactions Form 4 the moment they hit EDGAR.
- Analyze quarter-over-quarter trends with our Zoetis earnings report filing analysis.
- Quickly surface risk-factor changes by understanding Zoetis SEC documents with AI.
- Set alerts for Zoetis 8-K material events explained such as FDA approvals or recalls.
Every document is fetched from EDGAR the instant it posts, then distilled by expert models so you can move from data to decision without delay. Our dashboard offers Zoetis SEC filings explained simply, giving veterinarians, portfolio managers, and ag-sector analysts the regulatory signals that matter—minus the page-count fatigue.
Zoetis (ZTS): On 10/10/2025, an executive officer reported acquiring 201.7366 phantom stock units under the Zoetis Supplemental Savings Plan at $46.71 per unit.
After this transaction, the officer directly holds 28,624.727 derivative units. These phantom stock units track the value of Zoetis common stock plus a small cash-equivalent component and are settled in cash following separation from service. For this grant, the filing lists 66.7785 underlying shares of common stock.
Zoetis Inc. (ZTS) disclosed that its Chief Executive Officer and Director acquired 389.0627 phantom stock units on 10/10/2025 at $46.71 under the Zoetis Supplemental Savings Plan.
Each phantom unit’s value is tied to Zoetis common stock plus a cash-equivalent component and is settled in cash after separation from service.
Following this transaction, the reporting person beneficially owned 58,043.5681 derivative securities. The derivative position references 128.7869 shares of Zoetis common stock.
Zoetis (ZTS) disclosed a Form 4 showing its Executive Vice President acquired derivative securities tied to company stock. On 10/10/2025, the officer acquired 158.5078 phantom stock units at a price of $46.71, bringing total derivative holdings to 1,098.1566 units. These units reference Zoetis common stock; the filing lists an underlying amount of 52.469 shares for this transaction.
Per the plan terms, the phantom stock units are settled in cash following separation from service and may be reallocated among plan investment options subject to company limitations.
Zoetis (ZTS) Executive Vice President filed a Form 4 reporting an acquisition of phantom stock units under the Zoetis Supplemental Savings Plan on 10/10/2025. The filing shows the addition of 149.8609 phantom stock units at a derivative security price of $46.71, bringing total derivative holdings to 5,226.362 units, held directly.
These phantom stock units are settled in cash after separation from service, and their value tracks Zoetis common stock plus a small cash-equivalent component. Transfers among plan investment funds are permitted, subject to plan limits.
Roxanne Lagano, Executive Vice President of Zoetis Inc. (ZTS), reported a charitable gift of 700 shares of Zoetis common stock on 09/15/2025. The transaction is coded as a gift and carried no price. After the gift, Ms. Lagano directly beneficially owns 14,429 shares. She also holds the equivalent of 819.698 shares indirectly through the Zoetis Savings Plan (401(k)) as of June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/16/2025. The filing provides ownership levels and documents the charitable disposition; no option or derivative activity is reported.
Zoetis Inc. filed an 8-K reporting a material event: a Revolving Credit Agreement dated
FAQ
What is the current stock price of Zoetis (ZTS)?
What is the market cap of Zoetis (ZTS)?
